Literature DB >> 22308038

Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

An Wang1, Uzen Savas, Mei-Hui Hsu, C David Stout, Eric F Johnson.   

Abstract

Human cytochrome P450 2D6 contributes to the metabolism of >15% of drugs used in clinical practice. This study determined the structure of P450 2D6 complexed with a substrate and potent inhibitor, prinomastat, to 2.85 Å resolution by x-ray crystallography. Prinomastat binding is well defined by electron density maps with its pyridyl nitrogen bound to the heme iron. The structure of ligand-bound P450 2D6 differs significantly from the ligand-free structure reported for the P450 2D6 Met-374 variant (Protein Data Bank code 2F9Q). Superposition of the structures reveals significant differences for β sheet 1, helices A, F, F', G", G, and H as well as the helix B-C loop. The structure of the ligand complex exhibits a closed active site cavity that conforms closely to the shape of prinomastat. The closure of the open cavity seen for the 2F9Q structure reflects a change in the direction and pitch of helix F and introduction of a turn at Gly-218, which is followed by a well defined helix F' that was not observed in the 2F9Q structure. These differences reflect considerable structural flexibility that is likely to contribute to the catalytic versatility of P450 2D6, and this new structure provides an alternative model for in silico studies of substrate interactions with P450 2D6.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308038      PMCID: PMC3322812          DOI: 10.1074/jbc.M111.307918

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5.

Authors:  Michael R Wester; C David Stout; Eric F Johnson
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  Detection, delineation, measurement and display of cavities in macromolecular structures.

Authors:  G J Kleywegt; T A Jones
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-03-01

Review 4.  Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system.

Authors:  Magnus Ingelman-Sundberg; Sarah C Sim
Journal:  Biochem Biophys Res Commun       Date:  2010-05-21       Impact factor: 3.575

5.  Signal transduction in bacteria: CheW forms a reversible complex with the protein kinase CheA.

Authors:  J A Gegner; F W Dahlquist
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

6.  Crystal structure of human cytochrome P450 2D6.

Authors:  Paul Rowland; Frank E Blaney; Martin G Smyth; Jo J Jones; Vaughan R Leydon; Amanda K Oxbrow; Ceri J Lewis; Mike G Tennant; Sandeep Modi; Drake S Eggleston; Richard J Chenery; Angela M Bridges
Journal:  J Biol Chem       Date:  2005-12-13       Impact factor: 5.157

7.  Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.

Authors:  C L Crespi; D T Steimel; B W Penman; K R Korzekwa; P Fernandez-Salguero; J T Buters; H V Gelboin; F J Gonzalez; J R Idle; A K Daly
Journal:  Pharmacogenetics       Date:  1995-08

Review 8.  New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme.

Authors:  Bo Wang; Li-Ping Yang; Xiao-Zhuang Zhang; Shui-Qing Huang; Mark Bartlam; Shu-Feng Zhou
Journal:  Drug Metab Rev       Date:  2009       Impact factor: 4.518

9.  Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.

Authors:  S W Ellis; K Rowland; M J Ackland; E Rekka; A P Simula; M S Lennard; C R Wolf; G T Tucker
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

10.  Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen.

Authors:  Jason K Yano; Mei-Hui Hsu; Keith J Griffin; C David Stout; Eric F Johnson
Journal:  Nat Struct Mol Biol       Date:  2005-08-07       Impact factor: 15.369

View more
  34 in total

1.  In silico and in vivo evaluation of flavonoid extracts on CYP2D6-mediated herb-drug interaction.

Authors:  Zhe Su; Bo Zhang; Wenliang Zhu; Zhimin Du
Journal:  J Mol Model       Date:  2012-05-31       Impact factor: 1.810

2.  Molecular dynamics simulations give insight into the conformational change, complex formation, and electron transfer pathway for cytochrome P450 reductase.

Authors:  Axel Sündermann; Chris Oostenbrink
Journal:  Protein Sci       Date:  2013-08-01       Impact factor: 6.725

Review 3.  Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.

Authors:  Eric F Johnson; J Patrick Connick; James R Reed; Wayne L Backes; Manoj C Desai; Lianhong Xu; D Fernando Estrada; Jennifer S Laurence; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2013-10-15       Impact factor: 3.922

4.  Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6.

Authors:  Mara R Livezey; Erran D Briggs; Amanda K Bolles; Leslie D Nagy; Rina Fujiwara; Laura Lowe Furge
Journal:  Xenobiotica       Date:  2013-09-06       Impact factor: 1.908

5.  Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.

Authors:  R Leila Reynald; Stefaan Sansen; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2012-11-01       Impact factor: 5.157

Review 6.  Structural diversity of eukaryotic membrane cytochrome p450s.

Authors:  Eric F Johnson; C David Stout
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

7.  Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.

Authors:  Michael A Brodney; Elizabeth M Beck; Christopher R Butler; Gabriela Barreiro; Eric F Johnson; David Riddell; Kevin Parris; Charles E Nolan; Ying Fan; Kevin Atchison; Cathleen Gonzales; Ashley E Robshaw; Shawn D Doran; Mark W Bundesmann; Leanne Buzon; Jason Dutra; Kevin Henegar; Erik LaChapelle; Xinjun Hou; Bruce N Rogers; Jayvardhan Pandit; Ricardo Lira; Luis Martinez-Alsina; Peter Mikochik; John C Murray; Kevin Ogilvie; Loren Price; Subas M Sakya; Aijia Yu; Yong Zhang; Brian T O'Neill
Journal:  J Med Chem       Date:  2015-04-01       Impact factor: 7.446

Review 8.  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Authors:  Sung-Mi Kim; YongQiang Wang; Noushin Nabavi; Yi Liu; Maria Almira Correia
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

9.  Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.

Authors:  Amelia Nathania Dong; Nafees Ahemad; Yan Pan; Uma Devi Palanisamy; Beow Chin Yiap; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-26       Impact factor: 3.000

10.  Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules.

Authors:  Manish B Shah; P Ross Wilderman; Jaime Pascual; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2012-09-04       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.